Concepts (202)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Liver Transplantation | 22 | 2025 | 1030 | 4.740 |
Why?
|
| Cardiomyopathies | 6 | 2023 | 500 | 2.070 |
Why?
|
| Acute-On-Chronic Liver Failure | 4 | 2025 | 64 | 1.750 |
Why?
|
| Biliary Atresia | 4 | 2024 | 190 | 1.700 |
Why?
|
| Liver Cirrhosis | 7 | 2024 | 832 | 1.410 |
Why?
|
| Bile Acids and Salts | 5 | 2023 | 242 | 1.240 |
Why?
|
| Liver Failure, Acute | 4 | 2024 | 89 | 1.240 |
Why?
|
| Myocardium | 3 | 2021 | 1016 | 1.160 |
Why?
|
| End Stage Liver Disease | 5 | 2024 | 181 | 1.050 |
Why?
|
| Multiple Organ Failure | 3 | 2022 | 141 | 0.880 |
Why?
|
| Airway Extubation | 1 | 2024 | 66 | 0.860 |
Why?
|
| Liver | 4 | 2023 | 1743 | 0.820 |
Why?
|
| Renal Replacement Therapy | 3 | 2024 | 142 | 0.720 |
Why?
|
| Respiration, Artificial | 1 | 2023 | 464 | 0.700 |
Why?
|
| Perioperative Care | 1 | 2021 | 195 | 0.630 |
Why?
|
| Myocardial Contraction | 2 | 2018 | 267 | 0.630 |
Why?
|
| Tracheostomy | 1 | 2021 | 192 | 0.630 |
Why?
|
| Cholic Acids | 1 | 2018 | 16 | 0.610 |
Why?
|
| Critical Care | 2 | 2021 | 657 | 0.590 |
Why?
|
| Extracorporeal Circulation | 1 | 2018 | 55 | 0.590 |
Why?
|
| Receptors, G-Protein-Coupled | 2 | 2018 | 292 | 0.580 |
Why?
|
| Plasma Exchange | 1 | 2018 | 84 | 0.560 |
Why?
|
| Hemodynamics | 1 | 2021 | 850 | 0.560 |
Why?
|
| Cardiotonic Agents | 1 | 2018 | 139 | 0.550 |
Why?
|
| Cholic Acid | 3 | 2014 | 18 | 0.550 |
Why?
|
| Infant | 15 | 2024 | 12458 | 0.540 |
Why?
|
| Child | 23 | 2024 | 24339 | 0.480 |
Why?
|
| Retrospective Studies | 16 | 2024 | 16307 | 0.470 |
Why?
|
| Postoperative Complications | 3 | 2024 | 3070 | 0.440 |
Why?
|
| Liver Cirrhosis, Biliary | 1 | 2014 | 74 | 0.420 |
Why?
|
| Pyridines | 2 | 2014 | 230 | 0.420 |
Why?
|
| Hospital Costs | 2 | 2024 | 179 | 0.410 |
Why?
|
| Cholestasis | 2 | 2014 | 153 | 0.400 |
Why?
|
| Fibrinolytic Agents | 1 | 2014 | 205 | 0.390 |
Why?
|
| Thrombolytic Therapy | 1 | 2014 | 215 | 0.390 |
Why?
|
| Child, Preschool | 14 | 2024 | 13978 | 0.390 |
Why?
|
| Pulmonary Embolism | 1 | 2014 | 177 | 0.370 |
Why?
|
| Waiting Lists | 2 | 2021 | 226 | 0.360 |
Why?
|
| Male | 25 | 2024 | 61429 | 0.360 |
Why?
|
| Heart Atria | 1 | 2013 | 316 | 0.360 |
Why?
|
| Bile Duct Diseases | 1 | 2010 | 17 | 0.340 |
Why?
|
| Anticoagulants | 4 | 2022 | 593 | 0.320 |
Why?
|
| Cardiomyopathy, Hypertrophic | 1 | 2010 | 157 | 0.300 |
Why?
|
| Humans | 30 | 2025 | 125014 | 0.300 |
Why?
|
| Myocytes, Cardiac | 1 | 2013 | 625 | 0.300 |
Why?
|
| Thrombosis | 3 | 2022 | 525 | 0.300 |
Why?
|
| Diet, Atherogenic | 1 | 2008 | 16 | 0.300 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2011 | 369 | 0.290 |
Why?
|
| Citric Acid | 2 | 2018 | 37 | 0.290 |
Why?
|
| Prognosis | 4 | 2024 | 4628 | 0.290 |
Why?
|
| Hepatitis | 1 | 2008 | 57 | 0.280 |
Why?
|
| Adolescent | 10 | 2024 | 19320 | 0.280 |
Why?
|
| Blood Group Incompatibility | 2 | 2018 | 27 | 0.280 |
Why?
|
| Risk Factors | 6 | 2024 | 10282 | 0.270 |
Why?
|
| ABO Blood-Group System | 2 | 2018 | 66 | 0.270 |
Why?
|
| Mice, Knockout | 5 | 2023 | 3741 | 0.270 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2008 | 140 | 0.270 |
Why?
|
| Mice, Inbred C57BL | 6 | 2023 | 4403 | 0.260 |
Why?
|
| Liver Diseases | 2 | 2022 | 365 | 0.260 |
Why?
|
| Heart | 2 | 2011 | 728 | 0.260 |
Why?
|
| Atrial Fibrillation | 1 | 2013 | 659 | 0.260 |
Why?
|
| Length of Stay | 3 | 2024 | 1307 | 0.250 |
Why?
|
| Female | 18 | 2024 | 66709 | 0.240 |
Why?
|
| Heart Failure | 1 | 2018 | 2297 | 0.240 |
Why?
|
| Treatment Outcome | 8 | 2022 | 12383 | 0.230 |
Why?
|
| Critical Illness | 4 | 2021 | 601 | 0.220 |
Why?
|
| Ferritins | 2 | 2021 | 98 | 0.210 |
Why?
|
| Adenovirus Infections, Human | 1 | 2023 | 50 | 0.200 |
Why?
|
| Necrosis | 1 | 2022 | 206 | 0.190 |
Why?
|
| Intensive Care Units | 2 | 2018 | 491 | 0.190 |
Why?
|
| Gastroenterology | 1 | 2024 | 201 | 0.190 |
Why?
|
| Hemodiafiltration | 1 | 2021 | 18 | 0.190 |
Why?
|
| Fatty Acids | 2 | 2016 | 344 | 0.190 |
Why?
|
| Survival Rate | 2 | 2024 | 2057 | 0.180 |
Why?
|
| Animals | 9 | 2023 | 34210 | 0.170 |
Why?
|
| Bacterial Infections | 1 | 2023 | 307 | 0.170 |
Why?
|
| ADAMTS13 Protein | 1 | 2021 | 63 | 0.170 |
Why?
|
| Lymphohistiocytosis, Hemophagocytic | 2 | 2021 | 146 | 0.170 |
Why?
|
| Venous Thrombosis | 1 | 2022 | 183 | 0.170 |
Why?
|
| Gastroenteritis | 1 | 2023 | 349 | 0.170 |
Why?
|
| Disease Models, Animal | 3 | 2018 | 4390 | 0.170 |
Why?
|
| Bacteremia | 1 | 2023 | 406 | 0.160 |
Why?
|
| Ventricular Function, Left | 2 | 2014 | 508 | 0.160 |
Why?
|
| von Willebrand Factor | 1 | 2021 | 197 | 0.160 |
Why?
|
| Follow-Up Studies | 3 | 2024 | 5168 | 0.160 |
Why?
|
| Signal Transduction | 4 | 2018 | 4531 | 0.160 |
Why?
|
| Sepsis | 1 | 2023 | 480 | 0.160 |
Why?
|
| Cause of Death | 2 | 2018 | 474 | 0.160 |
Why?
|
| Serum Albumin, Human | 1 | 2018 | 7 | 0.150 |
Why?
|
| Hemofiltration | 1 | 2018 | 14 | 0.150 |
Why?
|
| Cytoprotection | 1 | 2018 | 38 | 0.150 |
Why?
|
| Biliary Tract Diseases | 1 | 2018 | 36 | 0.150 |
Why?
|
| Disseminated Intravascular Coagulation | 1 | 2018 | 68 | 0.150 |
Why?
|
| Preoperative Period | 1 | 2018 | 88 | 0.150 |
Why?
|
| Liver Failure | 1 | 2018 | 89 | 0.140 |
Why?
|
| Exercise Tolerance | 1 | 2018 | 85 | 0.140 |
Why?
|
| Survival Analysis | 1 | 2021 | 1504 | 0.140 |
Why?
|
| Combined Modality Therapy | 2 | 2018 | 1239 | 0.140 |
Why?
|
| Adaptation, Physiological | 1 | 2018 | 271 | 0.130 |
Why?
|
| Infant, Newborn | 4 | 2024 | 8194 | 0.130 |
Why?
|
| Echocardiography | 2 | 2019 | 1052 | 0.120 |
Why?
|
| Mice | 6 | 2023 | 17625 | 0.120 |
Why?
|
| Time Factors | 3 | 2017 | 6326 | 0.120 |
Why?
|
| Tissue Donors | 1 | 2018 | 494 | 0.110 |
Why?
|
| Acute Kidney Injury | 1 | 2021 | 635 | 0.110 |
Why?
|
| Retinoid X Receptor alpha | 1 | 2013 | 19 | 0.110 |
Why?
|
| Adrenergic beta-Agonists | 1 | 2014 | 94 | 0.110 |
Why?
|
| Drug Resistance | 1 | 2014 | 257 | 0.100 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2014 | 190 | 0.100 |
Why?
|
| Catheterization | 1 | 2014 | 236 | 0.100 |
Why?
|
| Cells, Cultured | 1 | 2018 | 3051 | 0.100 |
Why?
|
| Cardiovirus Infections | 1 | 2011 | 7 | 0.090 |
Why?
|
| Radiography | 1 | 2014 | 820 | 0.090 |
Why?
|
| Recovery of Function | 1 | 2014 | 445 | 0.090 |
Why?
|
| Adaptor Proteins, Vesicular Transport | 1 | 2011 | 45 | 0.090 |
Why?
|
| Portal Vein | 2 | 2022 | 94 | 0.090 |
Why?
|
| Consensus | 2 | 2025 | 639 | 0.090 |
Why?
|
| Dicarbethoxydihydrocollidine | 1 | 2010 | 3 | 0.090 |
Why?
|
| Ventricular Remodeling | 1 | 2011 | 184 | 0.090 |
Why?
|
| Glycogen | 1 | 2010 | 63 | 0.090 |
Why?
|
| Recurrence | 1 | 2014 | 1419 | 0.090 |
Why?
|
| Myocarditis | 1 | 2011 | 129 | 0.090 |
Why?
|
| Receptors, Adrenergic, beta | 1 | 2010 | 62 | 0.080 |
Why?
|
| Amino Acids | 2 | 2023 | 667 | 0.080 |
Why?
|
| Respiratory Function Tests | 1 | 2010 | 198 | 0.080 |
Why?
|
| Cohort Studies | 1 | 2019 | 4811 | 0.080 |
Why?
|
| Gene Expression | 2 | 2013 | 1561 | 0.080 |
Why?
|
| Oxygen Consumption | 1 | 2010 | 306 | 0.080 |
Why?
|
| Case-Control Studies | 2 | 2018 | 3298 | 0.080 |
Why?
|
| Fatigue | 1 | 2010 | 191 | 0.080 |
Why?
|
| Chemokine CXCL2 | 1 | 2008 | 4 | 0.070 |
Why?
|
| Fibrosis | 1 | 2010 | 434 | 0.070 |
Why?
|
| Cholesterol, Dietary | 1 | 2008 | 46 | 0.070 |
Why?
|
| Toll-Like Receptor 2 | 1 | 2008 | 56 | 0.070 |
Why?
|
| Chemokine CCL5 | 1 | 2008 | 53 | 0.070 |
Why?
|
| Chemokine CCL2 | 1 | 2008 | 122 | 0.070 |
Why?
|
| Heart Ventricles | 1 | 2011 | 768 | 0.070 |
Why?
|
| Ultrasonography | 1 | 2011 | 940 | 0.070 |
Why?
|
| Fatty Liver | 1 | 2008 | 187 | 0.060 |
Why?
|
| Dietary Fats | 1 | 2008 | 294 | 0.060 |
Why?
|
| Organ Dysfunction Scores | 1 | 2025 | 48 | 0.060 |
Why?
|
| Asia | 1 | 2025 | 107 | 0.060 |
Why?
|
| Biomarkers | 1 | 2014 | 3079 | 0.060 |
Why?
|
| Severity of Illness Index | 2 | 2024 | 2906 | 0.060 |
Why?
|
| Brain Edema | 1 | 2024 | 68 | 0.060 |
Why?
|
| India | 1 | 2024 | 214 | 0.060 |
Why?
|
| Receptors, Purinergic | 1 | 2023 | 15 | 0.050 |
Why?
|
| Receptors, Purinergic P2Y2 | 1 | 2023 | 16 | 0.050 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2017 | 1052 | 0.050 |
Why?
|
| Multivariate Analysis | 2 | 2017 | 1437 | 0.050 |
Why?
|
| Nucleotides | 1 | 2023 | 92 | 0.050 |
Why?
|
| Cytokines | 2 | 2023 | 1285 | 0.050 |
Why?
|
| Texas | 1 | 2011 | 3586 | 0.050 |
Why?
|
| Proportional Hazards Models | 2 | 2017 | 1356 | 0.050 |
Why?
|
| GTP-Binding Proteins | 1 | 2023 | 179 | 0.050 |
Why?
|
| Hepatic Artery | 1 | 2022 | 52 | 0.050 |
Why?
|
| Risk Assessment | 1 | 2011 | 3454 | 0.050 |
Why?
|
| Lipopolysaccharides | 1 | 2023 | 293 | 0.050 |
Why?
|
| Catheters | 1 | 2022 | 86 | 0.050 |
Why?
|
| RNA, Messenger | 1 | 2008 | 2821 | 0.050 |
Why?
|
| Arginine | 1 | 2023 | 333 | 0.050 |
Why?
|
| Health Care Costs | 1 | 2024 | 371 | 0.040 |
Why?
|
| Thrombectomy | 1 | 2021 | 107 | 0.040 |
Why?
|
| Oxidoreductases | 1 | 2021 | 92 | 0.040 |
Why?
|
| Phenotype | 1 | 2010 | 4259 | 0.040 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2021 | 119 | 0.040 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 1 | 2021 | 96 | 0.040 |
Why?
|
| Societies, Medical | 1 | 2024 | 695 | 0.040 |
Why?
|
| Prospective Studies | 2 | 2021 | 6152 | 0.040 |
Why?
|
| Gene Deletion | 1 | 2023 | 788 | 0.040 |
Why?
|
| Adenoviridae | 1 | 2023 | 604 | 0.040 |
Why?
|
| Graft Survival | 1 | 2022 | 535 | 0.040 |
Why?
|
| Clinical Protocols | 1 | 2018 | 239 | 0.030 |
Why?
|
| Recombinant Proteins | 1 | 2021 | 1399 | 0.030 |
Why?
|
| United States | 2 | 2024 | 10905 | 0.030 |
Why?
|
| Linear Models | 1 | 2018 | 680 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2018 | 1168 | 0.030 |
Why?
|
| Graft Rejection | 1 | 2018 | 589 | 0.030 |
Why?
|
| Renal Dialysis | 1 | 2021 | 854 | 0.030 |
Why?
|
| Immunosuppressive Agents | 1 | 2018 | 650 | 0.030 |
Why?
|
| Mice, Inbred DBA | 1 | 2013 | 48 | 0.030 |
Why?
|
| Mice, 129 Strain | 1 | 2013 | 98 | 0.030 |
Why?
|
| Mutant Proteins | 1 | 2013 | 114 | 0.030 |
Why?
|
| Mice, Mutant Strains | 1 | 2013 | 384 | 0.030 |
Why?
|
| Disease Progression | 1 | 2018 | 2061 | 0.020 |
Why?
|
| Calcium | 1 | 2017 | 1101 | 0.020 |
Why?
|
| Hospital Mortality | 1 | 2017 | 1025 | 0.020 |
Why?
|
| Hepatocytes | 1 | 2013 | 208 | 0.020 |
Why?
|
| Adult | 2 | 2024 | 29620 | 0.020 |
Why?
|
| Encephalomyocarditis virus | 1 | 2011 | 8 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 1 | 2013 | 766 | 0.020 |
Why?
|
| Young Adult | 1 | 2024 | 9045 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2011 | 824 | 0.020 |
Why?
|
| Viral Load | 1 | 2011 | 385 | 0.020 |
Why?
|
| Peptide Fragments | 1 | 2013 | 780 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2011 | 504 | 0.020 |
Why?
|
| Age Factors | 1 | 2016 | 2816 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2011 | 1103 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2011 | 1290 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2011 | 1694 | 0.020 |
Why?
|
| Apoptosis | 1 | 2013 | 1803 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2011 | 2397 | 0.020 |
Why?
|